Novo Nordisk A/S (NYSE:NVO) is included among the 12 Best European Dividend Stocks to Buy Now.
On November 14, Berenberg lowered its price target on Novo Nordisk A/S to DKK 400 from DKK 425 while maintaining a Buy rating on the shares, according to a report by The Fly.
Novo Nordisk A/S recently announced a price cut to compete with Eli Lilly (LLY) in the obesity-drug market, signaling a more aggressive effort to regain U.S. market share. For the first two months, the drugs will be available through Novo’s direct-to-consumer NovoCare portal at $349 per month, which is around 30% below current self-pay pricing. The self-pay cost for Ozempic 2mg will remain $499 per month.
In the third quarter of 2025, Novo Nordisk A/S reported revenue of DKK 154.94 billion, up 16.1% year-on-year. Operating profit rose 25%, while sales in the Diabetes and Obesity care segment increased 16%. Free cash flow reached DKK 33.6 billion, and the company returned DKK 35.6 billion to shareholders.
Novo Nordisk A/S is a global healthcare company that develops and manufactures treatments for serious chronic diseases, historically focusing on diabetes.
READ NEXT: 15 Best 52-Week Low Dividend Stocks to Invest In and 15 Best Passive Income Stocks to Buy Right Now.
